Ovid Therapeutics to Present at Upcoming August Investor Conferences

Rhea-AI Summary

Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company focused on improving lives affected by epilepsies and brain conditions, has announced its participation in two upcoming investor conferences in August 2024:

1. BTIG Virtual Biotechnology Conference: Ovid will engage in a fireside chat on Tuesday, August 6th at 10:00 a.m. ET.

2. 2024 Wedbush PacGrow Healthcare Conference: The company will participate in a panel discussion on Tuesday, August 13th at 10:15 a.m. ET.

Both events will be accessible via live webcasts through the Events & Presentations section of Ovid's website at investors.ovidrx.com. Archived replays will be available on the company's website following the live presentations.

NEW YORK, July 30, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to meaningfully improving the lives of people affected by certain epilepsies and brain conditions, today announced that management will participate in two upcoming investor conferences in August:

• BTIG Virtual Biotechnology Conference – Ovid will participate in a fireside chat on Tuesday, August 6^th at 10:00 a.m. ET.
• 2024 Wedbush PacGrow Healthcare Conference – Ovid will participate in a panel discussion on Tuesday, August 13^th at 10:15 a.m. ET.

Live webcasts of the fireside chat and panel discussion can be accessed through the Events & Presentations section of the Company’s website at investors.ovidrx.com. An archived replay of the webcast will be available on the Company’s website following the live presentation.

About Ovid Therapeutics

Ovid Therapeutics Inc. is a New York-based biopharmaceutical company that is dedicated to improving the lives of people affected by certain epilepsies and brain conditions with seizure symptoms. The Company is advancing a pipeline of novel, targeted small molecule candidates that modulate the intrinsic and extrinsic factors involved in neuronal hyperexcitability causative of seizures and other neurological symptoms. Ovid is developing: OV888/GV101 capsule, a potent and highly selective ROCK2 inhibitor capsule, for the potential treatment of cerebral cavernous malformations and other rare central nervous system diseases; OV329, a GABA-aminotransferase inhibitor, a potential therapy for treatment-resistant seizures; and OV350, a direct activator of the KCC2 transporter, for the potential treatment of epilepsies and other psychiatric conditions. For more information about these and other Ovid research programs, please visit www.ovidrx.com.

Contacts

Investor Relations:
Garret Bonney
617-735-6093
IR@ovidrx.com

FAQ

When is Ovid Therapeutics participating in the BTIG Virtual Biotechnology Conference?

Ovid Therapeutics is participating in the BTIG Virtual Biotechnology Conference on Tuesday, August 6th, 2024, at 10:00 a.m. ET with a fireside chat.

What investor conferences is Ovid Therapeutics (OVID) attending in August 2024?

Ovid Therapeutics (OVID) is attending two investor conferences in August 2024: the BTIG Virtual Biotechnology Conference on August 6th and the 2024 Wedbush PacGrow Healthcare Conference on August 13th.

How can investors access Ovid Therapeutics' presentations at the August 2024 conferences?

Investors can access live webcasts of Ovid Therapeutics' presentations through the Events & Presentations section of the company's website at investors.ovidrx.com. Archived replays will also be available after the live events.

What type of event is Ovid Therapeutics participating in at the 2024 Wedbush PacGrow Healthcare Conference?

Ovid Therapeutics is participating in a panel discussion at the 2024 Wedbush PacGrow Healthcare Conference on Tuesday, August 13th, 2024, at 10:15 a.m. ET.